tetano
Editor, Senior Moderator
Open Med (Wars)
. 2022 Jan 24;17(1):216-220.
doi: 10.1515/med-2021-0374. eCollection 2022.
The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
Edyta Reichman-Warmusz[SUP] 1 [/SUP], Oliwia Warmusz[SUP] 2 [/SUP], Romuald Wojnicz[SUP] 1 3 [/SUP]
Affiliations
Abstract
Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular weight heparin (LMWH) was associated with lower mortality in this cohort of patients. However, the timing of starting LMWH and the dose remain controversial in COVID-19 patients. Considering the above, the aim of this study was to reveal the rationale for using LMWH in the therapy of symptomatic COVID-19 patients based on experimental and clinical studies on LMWH in inflammatory settings with special consideration given to randomized trials.
Keywords: COVID-19; anticoagulation; inflammation; low-molecular weight heparin; microvascular coagulapathy.
. 2022 Jan 24;17(1):216-220.
doi: 10.1515/med-2021-0374. eCollection 2022.
The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
Edyta Reichman-Warmusz[SUP] 1 [/SUP], Oliwia Warmusz[SUP] 2 [/SUP], Romuald Wojnicz[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35178474
- PMCID: PMC8812716
- DOI: 10.1515/med-2021-0374
Abstract
Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular weight heparin (LMWH) was associated with lower mortality in this cohort of patients. However, the timing of starting LMWH and the dose remain controversial in COVID-19 patients. Considering the above, the aim of this study was to reveal the rationale for using LMWH in the therapy of symptomatic COVID-19 patients based on experimental and clinical studies on LMWH in inflammatory settings with special consideration given to randomized trials.
Keywords: COVID-19; anticoagulation; inflammation; low-molecular weight heparin; microvascular coagulapathy.